277 related articles for article (PubMed ID: 25649020)
1. Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.
Rafii S; Roda D; Geuna E; Jimenez B; Rihawi K; Capelan M; Yap TA; Molife LR; Kaye SB; de Bono JS; Banerji U
Clin Cancer Res; 2015 Apr; 21(8):1869-76. PubMed ID: 25649020
[TBL] [Abstract][Full Text] [Related]
2. Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials.
Geuna E; Roda D; Rafii S; Jimenez B; Capelan M; Rihawi K; Montemurro F; Yap TA; Kaye SB; De Bono JS; Molife LR; Banerji U
Br J Cancer; 2015 Dec; 113(11):1541-7. PubMed ID: 26554652
[TBL] [Abstract][Full Text] [Related]
3. Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies.
Aggarwal R; Grabowsky J; Strait N; Cockerill A; Munster P
Cancer Chemother Pharmacol; 2014 Aug; 74(2):359-65. PubMed ID: 24934865
[TBL] [Abstract][Full Text] [Related]
4. Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management.
Khan KH; Wong M; Rihawi K; Bodla S; Morganstein D; Banerji U; Molife LR
Oncologist; 2016 Jul; 21(7):855-60. PubMed ID: 27151652
[TBL] [Abstract][Full Text] [Related]
5. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
van der Ploeg P; Uittenboogaard A; Thijs AMJ; Westgeest HM; Boere IA; Lambrechts S; van de Stolpe A; Bekkers RLM; Piek JMJ
Gynecol Oncol; 2021 Nov; 163(2):433-444. PubMed ID: 34253390
[TBL] [Abstract][Full Text] [Related]
7. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
Alzahrani AS
Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
Janku F; Wheler JJ; Naing A; Falchook GS; Hong DS; Stepanek VM; Fu S; Piha-Paul SA; Lee JJ; Luthra R; Tsimberidou AM; Kurzrock R
Cancer Res; 2013 Jan; 73(1):276-84. PubMed ID: 23066039
[TBL] [Abstract][Full Text] [Related]
9. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.
Gonzalez-Angulo AM; Blumenschein GR
Cancer Treat Rev; 2013 Jun; 39(4):313-20. PubMed ID: 23218708
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
[TBL] [Abstract][Full Text] [Related]
11. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
12. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.
Lim HJ; Crowe P; Yang JL
J Cancer Res Clin Oncol; 2015 Apr; 141(4):671-89. PubMed ID: 25146530
[TBL] [Abstract][Full Text] [Related]
13. Development of PI3K inhibitors: lessons learned from early clinical trials.
Rodon J; Dienstmann R; Serra V; Tabernero J
Nat Rev Clin Oncol; 2013 Mar; 10(3):143-53. PubMed ID: 23400000
[TBL] [Abstract][Full Text] [Related]
14. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
Burris HA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
[TBL] [Abstract][Full Text] [Related]
15. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges.
Cheaib B; Auguste A; Leary A
Chin J Cancer; 2015 Jan; 34(1):4-16. PubMed ID: 25556614
[TBL] [Abstract][Full Text] [Related]
16. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.
Dienstmann R; Rodon J; Serra V; Tabernero J
Mol Cancer Ther; 2014 May; 13(5):1021-31. PubMed ID: 24748656
[TBL] [Abstract][Full Text] [Related]
17. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.
LoPiccolo J; Blumenthal GM; Bernstein WB; Dennis PA
Drug Resist Updat; 2008; 11(1-2):32-50. PubMed ID: 18166498
[TBL] [Abstract][Full Text] [Related]
19. Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway.
Patel S
Curr Oncol Rep; 2013 Aug; 15(4):386-95. PubMed ID: 23605780
[TBL] [Abstract][Full Text] [Related]
20. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
